UA137802U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), thrombomodulin, folic acid, homocysteine, interleukin 6 (IL-6) genes is determined in the patient's serum. With a homozygous carrier of 677-TT, 786-CC and levels of thrombomodulin> 5 ng / ml, folic acid <6 ng / ml, homocysteine> 20 μmol / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (TSA.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (2ЕМО5 1786С), the content of thrombomodulin, folic acid, homocysteine, interleukin 6 ( IL-6). With homozygous carriers of 677-HT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-6 210 ng/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of thrombomodulin, folic acid, homocysteine, and IL-6 is determined by the immunoenzymatic method. With homozygous carrier 67 7-1, 786-

SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-6 "10 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient P., 59 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEV C677T and emo5 17860 genes were determined in blood serum. The content of thrombomodulin, folic acid, homocysteine, and IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of thrombomodulin - 13 ng/ml, folic acid - 2.9 ng/ml, homocysteine - 32 μmol/l, IL-6-23 ng/l. The development of osteoarthritis was diagnosed. After 11

For months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphism of the genes methylenetetrahydrofolate reductase (МТНЕВ С677Т), nitric oxide synthase (2ЕМО5 1786С), the content of thrombomodulin, folic acid, homocysteine, interleukin b ( IL-b6) and with homozygous carriers of 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, homocysteine 220 μmol/l, IL-6 210 ng/l predict the development of osteoarthritis.